Nova Eye Delivers Record December Quarter as Global Sales Momentum Accelerates
Nova Eye Medical Limited (ASX: EYE) has reported its strongest December quarter on record, underpinned by sustained growth across key global markets. Quarterly sales reached US$ 6.1 million, representing an increase of thirty-eight percent compared with the prior corresponding period and twenty-five percent over the September quarter. Sales for the six months to thirty-one December two thousand and twenty-five totalled US$ 10.9 million, reflecting year-on-year growth of twenty-nine percent. On a rolling twelve-month basis, group revenue reached approximately US$ 21.0 million, equivalent to AU$ 32.2 million, marking twenty-four percent growth and materially outperforming broader industry expansion. Growth continues to be led by the United States, where Nova Eye has delivered six consecutive halves of sales growth since the launch of iTrack Advance, achieving an estimated compound annual growth rate of around forty percent. Expanding adoption of minimally invasive glaucoma procedures continues to support strong demand globally.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Nova Eye Delivers Record December Quarter as Global Sales Momentum Accelerates
Nova Eye Medical Limited (ASX: EYE) has reported its strongest December quarter on record, underpinned by sustained growth across key global markets. Quarterly sales reached US$ 6.1 million, representing an increase of thirty-eight percent compared with the prior corresponding period and twenty-five percent over the September quarter. Sales for the six months to thirty-one December two thousand and twenty-five totalled US$ 10.9 million, reflecting year-on-year growth of twenty-nine percent. On a rolling twelve-month basis, group revenue reached approximately US$ 21.0 million, equivalent to AU$ 32.2 million, marking twenty-four percent growth and materially outperforming broader industry expansion. Growth continues to be led by the United States, where Nova Eye has delivered six consecutive halves of sales growth since the launch of iTrack Advance, achieving an estimated compound annual growth rate of around forty percent. Expanding adoption of minimally invasive glaucoma procedures continues to support strong demand globally.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au